Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin Dosages in Induction Treatment of AML
NCT00474006Phase 3Completed
- Sponsor
- Japan Adult Leukemia Study Group
- Start
- Aug 2001
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by Japan Adult Leukemia Study Group. Primary endpoints: Toxicities at 10 years, Complete Remission Rate at 10 years and 3 more. Started Aug 2001; status: completed.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00474006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00474006.